Updated Results of the COVID-19 in MS Global Data Sharing InitiativeSteve Simpson, Liesbet M. Peeters, Ashkan Pirmani et al.|Neurology Neuroimmunology & Neuroinflammation|2022Cited by 53
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Tomáš Kalinčík, Bianca Weinstock-Guttman et al.|JAMA Neurology|2025Cited by 43
Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic studyBilgin Öztürk, Şuayıp Birinci, Esra Taşkıran et al.|Multiple Sclerosis Journal|2024Cited by 25
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple SclerosisHans‐Peter Hartung, Joep Killestein, Ralph H. B. Benedict et al.|Neurology|2024Cited by 15
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12